Therapies for type 2 diabetes: Lowering HbA1c and associated cardiovascular risk factors

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Kurukulasuriya, L Romayne ^a   Sowers, James R ^a,b  

^a UMC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNINDEXED DRUG; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ANTIOXIDANT ACTIVITY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; FLATULENCE; FLUID RETENTION; FRACTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; MONOTHERAPY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; METABOLISM; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS;

EID: 77956471187     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-45     Document Type: Review

References (102)

1. National Diabetes Information Clearing House (NDIC) National Diabetes Statistics, 2007. Last updated: June 2008. Accessed: December 4, 2009, National Diabetes Information Clearing House (NDIC)., http://diabetes.niddk.nih.gov/DM/PUBS/statistics/
2. Khavandi K, Khavandi A, Asghar O, Greenstein A, Withers S, Heagerty AM, Malik RA. Diabetic cardiomyopathy--a distinct disease?. Best Pract Res Clin Endocrinol Metab 2009, 23:347-360. 10.1016/j.beem.2008.10.016, 19520308.
3. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21-e181. 10.1161/CIRCULATIONAHA.108.191261, 19075105.
4. Pieske B, Wachter R. Impact of diabetes and hypertension on the heart. Curr Opin Cardiol 2008, 23:340-349. 10.1097/HCO.0b013e3283031ab3, 18520718.
5. Sowers J, Stump C. Insights into the biology of diabetic vascular disease: what's new?. Am J Hypertens 2004, 17:2S-6S. 10.1016/j.amjhyper.2004.08.007, 15539107.
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412. 10.1136/bmj.321.7258.405, 27454, 10938048.
7. Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2008, 358:2633-2635. 10.1056/NEJMe0803831, 18539919.
8. Kelly T, Bazzano L, Fonseca V, Theti T, Reynolds K, Jiang H. Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:1-13.
9. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erquo S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772. 10.1016/S0140-6736(09)60697-8, 19465231.
10. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143-3421. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
11. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007, 30:753-759. 10.2337/dc07-9920, 17327355.
12. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ) 2005, 128:1-11.
13. Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care 2008, 31:1582-1584. 10.2337/dc08-0025, 2494632, 18458146.
14. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007, 61:737-747. 10.1111/j.1742-1241.2007.01336.x, 1890993, 17493087.
15. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001, 9(suppl 4):326S-334S. 10.1038/oby.2001.138, 11707561.
16. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003, 22:331-339.
17. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbjornsdottir S, Eliasson B. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009, 52:65-73. 10.1007/s00125-008-1190-x, 18985314.
18. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care 2008, 31:1686-1696. 10.2337/dc08-9022, 2494659, 18663233.
19. Leiter LA, Fitchett D. Optimal care of cardiovascular disease and type 2 diabetes patients: shared responsibilities between the cardiologist and diabetologist. Atheroscler Suppl 2006, 7:37-42. 10.1016/j.atherosclerosissup.2006.01.006, 16516560.
20. American Association of Clinical Endocrinologists (AACE) Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007, 13(suppl 1):3-68. American Association of Clinical Endocrinologists (AACE).
21. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203. 10.2337/dc08-9025, 2606813, 18945920.
22. American Diabetes Association Standards of medical care in diabetes--2009. Diabetes Care 2009, 32(suppl 1):S13-S61. 2613589, 19118286, American Diabetes Association.
23. Wing RR, Marquez B. Behavioral aspects of weight loss in type 2 diabetes. Curr Diab Rep 2008, 8:126-131. 10.1007/s11892-008-0023-0, 18445355.
24. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz S. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract 2009, 15:541-559.
25. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206. 10.1001/jama.298.2.194, 17622601.
26. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006, 29:2137-2139. 10.2337/dc06-1120, 16936168.
27. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. 10.1016/S0140-6736(98)07019-6, 9742976, UK Prospective Diabetes Study (UKPDS) Group.
28. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006, 49:1761-1769. 10.1007/s00125-006-0297-1, 16736131.
29. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589. 10.1056/NEJMoa0806470, 18784090.
30. Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. J Clin Pharm Ther 2009, 34:13-23. 10.1111/j.1365-2710.2008.00984.x, 19125899.
31. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250. 10.1016/S0140-6736(08)61206-4, 18782641.
32. Hoogwerf BJ, Doshi KB, Diab D. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag 2008, 4:355-362. 2496974, 18561511.
33. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000, 40:49-57. 10.1177/00912700022008694, 10631622.
34. Lingvay I, Kaloyanova PF, Adams-Huet B, Salinas K, Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med 2007, 55:62-68. 10.2310/6650.2007.06036, 17362692.
35. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 2006, 4:CD005061.
36. Eleftheriadou I, Grigoropoulou P, Katsilambros N, Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr Diabetes Rev 2008, 4:340-356. 10.2174/157339908786241133, 18991602.
37. Zinman B. PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab 2001, 3(suppl 1):S34-S43. 10.1046/j.1463-1326.2001.00033.x, 11685828.
38. Kawai T, Funae O, Shimada A, Tabata M, Hirata T, Atsumi Y, Itoh H. Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. Intern Med 2008, 47:1181-1188. 10.2169/internalmedicine.47.0969, 18591838.
39. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008, 10:1204-1211.
40. Norris SL, Carson S, Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Curr Diabetes Rev 2007, 3:127-140. 10.2174/157339907780598216, 18220664.
41. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabet Med 2005, 22:980-985. 10.1111/j.1464-5491.2005.01656.x, 16026361.
42. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635. 10.2337/diacare.27.11.2628, 15504997.
43. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47. 10.1016/S0140-6736(09)60659-0, 19515413.
44. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100. 10.2337/diacare.28.5.1092, 15855572.
45. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091. 10.2337/diacare.28.5.1083, 15855571.
46. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
47. Zinman B, Hoogwerf BJ, Duran GS, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007, 146:477-485.
48. Drucker D, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, . for the DURATION-1-Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, noninferiority study. Lancet 2008, 372:1240-1250. 10.1016/S0140-6736(08)61206-4, 18782641, for the DURATION-1-Study Group.
49. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481. 10.1016/S0140-6736(08)61246-5, 18819705.
50. Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD) trial. Expert Rev Endocrinol Metab 2009, 4:119-129.
51. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009, 32:84-90. 10.2337/dc08-1355, 2606836, 18931095.
52. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230. 10.2337/dc08-2124, 2699702, 19289857.
53. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705. 10.1016/S0140-6736(06)69705-5, 17098089.
54. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005, 78:675-688. 10.1016/j.clpt.2005.09.002, 16338283.
55. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637. 10.2337/dc06-0703, 17130196.
56. DeFronzo RA, Hissa MN, Garber AJ, Luiz GJ, Yuyan DR, Ravichandran S, Chen RS. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32:1649-1655. 10.2337/dc08-1984, 19478198.
57. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008, 24:537-550. 10.1185/030079908X260925, 18194595.
58. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256-263. 10.2337/diacare.27.1.256, 14693998.
59. Takeda Pharmaceuticals North America, Inc ACTOS® (pioglitazone HCl) prescribing information. Last updated: September 2009. Accessed December 4, 2009, Takeda Pharmaceuticals North America, Inc., http://www.actos.com/actos/prescribinginfo.aspx
60. Kline G. AVANDIA® (roaglitazone maleate) prescribing information. Last updated: February 2009. Accessed December 4, 2009., http://us.gsk.com/products/assets/us_avandia.pdf
61. Yilmaz H, Gursoy A, Sahin M, Guvener DN. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetol 2007, 44:187-192. 10.1007/s00592-007-0004-9, 17726570.
62. Kusaka I, Nagasaka S, Horie H, Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?. Diabetes Obes Metab 2008, 10:1039-1046. 10.1111/j.1463-1326.2008.00857.x, 18355332.
63. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571. 10.1007/s00125-006-0416-z, 17001471.
64. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009, 25:2401-2411. 10.1185/03007990903178735, 19650754.
65. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:959-969. 10.1111/j.1463-1326.2007.00839.x, 18201203.
66. Bergenstal R, Kim T, Trautmann M, Zhuang D, Okerson T, Taylor K. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes (abstract no. LAR-105). Circulation 2008, 118.
67. Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O. Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr Pract 2008, 14:993-999.
68. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952. 10.1185/03007990802418851, 18786299.
69. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG, . for the Pramlintide in Type 2 Diabetes Group Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. Diabetes Care 1998, 21:987-993. 10.2337/diacare.21.6.987, 9614619, for the Pramlintide in Type 2 Diabetes Group.
70. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Wyer C. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004, 12:661-668. 10.1038/oby.2004.76, 15090634.
71. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114-126. 10.1161/CIRCULATIONAHA.106.179294, 17192512.
72. Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs 2005, 5:201-209. 10.2165/00129784-200505030-00006, 15901207.
73. Steiner G. A new perspective in the treatment of dyslipidemia: can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?. Treat Endocrinol 2005, 4:311-317. 10.2165/00024677-200504050-00004, 16185099.
74. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternack RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239. 10.1161/01.CIR.0000133317.49796.0E, 15249516.
75. Papanas N, Tziakas D, Chalikias G, Floros D, Trypsianis G, Papadopoulou E, Kortsaris A, Symeonidis G, Souliou E, Maltezos E, Hatseras D. Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. Diabetes Metab 2006, 32:344-349. 10.1016/S1262-3636(07)70289-6, 16977262.
76. Sliwinska A, Blasiak J, Kasznicki J, Drewoski J. In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM). Chem Biol Interact 2008, 173:159-165. 10.1016/j.cbi.2008.03.017, 18485337.
77. Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006, 53:87-94. 10.2152/jmi.53.87, 16538000.
78. Manzella D, Grella R, Abbatecola AM, Paolisso G. Repaglinide adminstration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005, 28:366-371. 10.2337/diacare.28.2.366, 15677794.
79. Johansen OE, Birkeland KI. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Am J Cardiovasc Drugs 2007, 7:319-335. 10.2165/00129784-200707050-00002, 17953471.
80. Yngen M, Ostenson CG, Hjemdahl P, Wallén NH. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabet Med 2006, 23:134-140. 10.1111/j.1464-5491.2005.01765.x, 16433710.
81. Esposito K, Giugliano D, Nappo F, Marfella R, . for the Campanian Postprandial Hyperglycemia Study Group Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004, 110:214-219. 10.1161/01.CIR.0000134501.57864.66, 15197140, for the Campanian Postprandial Hyperglycemia Study Group.
82. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004, 256:1-14. 10.1111/j.1365-2796.2004.01328.x, 15189360.
83. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A Study of two ethnic groups. Diabetes Care 1993, 16:621-629. 10.2337/diacare.16.4.621, 8462390.
84. Derosa G, Fogari E, Cicero AFG, D'angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SAT, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007, 30:387-394. 10.1291/hypres.30.387, 17587750.
85. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 2009, 302:1186-1194. 10.1001/jama.2009.1347, 19755697.
86. De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005, 257:100-109. 10.1111/j.1365-2796.2004.01420.x, 15606381.
87. Karagiannis E, Pfutzner A, Forst T, Lubben G, Roth W, Grabellus M, Flannery M, Schondorf T. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther 2008, 10:206-212. 10.1089/dia.2008.0244, 18473695.
88. Abbasi F, Lima NK, Reaven GM. Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Metabolism 2009, 58:373-378. 10.1016/j.metabol.2008.10.011, 19217454.
89. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control. J Am Coll Cardiol 2005, 45:1925-1931. 10.1016/j.jacc.2005.03.041, 15963388.
90. Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?. Curr Pharm Design 2009, 15:3179-3192.
91. Kalaitzidis RG, Sarafidis PA, Bakris GL. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Design 2009, 15:529-536.
92. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J Am Coll Cardiol 2007, 49:290-297. 10.1016/j.jacc.2006.08.054, 17239709.
93. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006, 29:554-559. 10.2337/diacare.29.03.06.dc05-0695, 16505505.
94. Maggs D, Bhole D, Yan P, Stonehouse A, Brodows R, Okerson T. Exenatide is superior to insulin in attaining tight glycaemic control (HbA1c ≤ 6.5%) with a more favourable accompanying metabolic profile (abstract no. 876). Program and abstracts of the European Association for the Study of Diabetes (EASD) 44th Annual Meeting; September 7-11, 2008; Rome, Italy
95. Okerson T, Yan P, Stonehouse A, Brodows R, Bhole D. Exenatide improved systolic blood pressure compared to insulin or placebo in patients with type 2 diabetes (abstract no. 877). Program and abstracts of the European Association for the Study of Diabetes (EASD) 44th Annual Meeting; September 7-11, 2008; Rome, Italy
96. Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res Clin Pract 2007, 77:180-187. 10.1016/j.diabres.2006.12.011, 17239474.
97. Bergenstal R, Kim T, Trautmann M, Okerson T, Taylor K. Exenatide once weekly elicited improvements in blood pressure and lipid profile over 52 weeks in patients with type 2 diabetes (abstract no. 1239). Circulation 2008, 118:S1086.
98. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 2010, 12:233-240. 10.1089/dia.2009.0141, 20151774.
99. Pettigrew KA, McKnight AJ, Martin RJ, Patterson CC, Kilner J, Sadliert D, Maxwell AP, Savage DA, . for the Warren 3/UK GoKinD Study Group Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabetic Med 2008, 25:1129-1131. 10.1111/j.1464-5491.2008.02540.x, 2592347, 19183322, for the Warren 3/UK GoKinD Study Group.
100. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008, 48:592-598. 10.1177/0091270008316885, 18353996.
101. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intimamedia thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004, 35:1073-1078. 10.1161/01.STR.0000125864.01546.f2, 15073402.
102. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, . for the STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494. 10.1001/jama.290.4.486, 12876091, for the STOP-NIDDM Trial Research Group.